<DOC>
	<DOC>NCT01169987</DOC>
	<brief_summary>This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.</brief_summary>
	<brief_title>Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients &gt; or = 18 years Patient with chronic plaque psoriasis Patient newly initiated on Humira Patient compliant with Humira Summary of Product Characteristics Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis Patient has signed informed consent Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira Patients not willing to sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multicenter study</keyword>
</DOC>